2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Bioinformatics, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Bispecific Antibody Therapy, Immunotherapy, Non-Biological Therapies, Chemotherapy, Pharmacology, Artificial Intelligence (AI), Machine Learning, Biological Processes, Apoptosis, Pathogenesis, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Fundamental Science, AML, Translational Research, MDS, Clinical Research, Clinical Trials, Study Population, Human, Adult, Pediatric, Animal Model
PAPER

1490 Wild-type IDH1/2 inhibition creates a G6PD-dependent de-novo pyrimidine biosynthetic dependency in acute myeloid leukemia

Meng Liu, MD, Umesh Prasad Yadav, PhD2, Jianai Sun3, Lei Zhang, MD4, Xin He, MD5, Haojie Dong, PhD6, Shuaishuai Ge, MS7, Yini Wang8, Le Xuan Truong Nguyen, PhD9, Bin Zhang, PhD10, Ya-Huei Kuo, PhD11, Steven T Rosen, MD12, Jian Xu, PhD13, Amandeep Salhotra, MD14, Guido Marcucci, MD15, Ling Li, PhD16
1 City of Hope National Medical Center, Duarte, California, United States
2 Loma Linda University, Loma Linda, California, United States
3 the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
4 City of Hope National Medical Center, Duarte, California, United States
5 City of Hope National Medical Center, Duarte, California, United States
6 City of Hope National Medical Center, Duarte, California, United States
7 City of Hope National Medical Center, Duarte, California, United States
8 City of Hope National Medical Center, Duarte, California, United States
9 City of Hope National Medical Center, Duarte, California, United States
10 City of Hope National Medical Center, Duarte, California, United States
11 City of Hope National Medical Center, Duarte, California, United States
12 City of Hope National Medical Center, Duarte, California, United States
13 Saint Jude Children's Research Hospital, Memphis, Tennessee, United States
14 City of Hope National Medical Center, Duarte, California, United States
15 City of Hope National Medical Center, Duarte, California, United States
16 City of Hope National Medical Center, Duarte, California, United States

Background: Although mutant IDH1/2 have been extensively studied in acute myeloid leukemia (AML), the metabolic functions of their wild-type counterparts remain poorly defined. Because IDH1/2 mutations are typically heterozygous, catalytically active wild-type IDH1/2 are retained in both IDH-mutant and IDH-wild-type AML, suggesting broader roles in leukemia metabolism. Together with the oxidative pentose phosphate pathway (oxPPP), wild-type IDH1/2 constitute major cellular sources of NADPH. We hypothesized that disruption of wild-type IDH1/2 would perturb NADPH homeostasis, trigger adaptive metabolic rewiring, and expose therapeutically targetable metabolic liabilities.

Methods: Wild-type IDH1/2 function was interrogated using clinically developed mutant IDH inhibitors as pharmacologic probes under experimentally validated conditions. Brequinar was used for mechanistic studies unless otherwise indicated, also with leflunomide included for therapeutic validation as a clinically available DHODH inhibitor. Metabolic dependencies were identified using a focused CRISPR/Cas9 screen targeting ~3,000 metabolic genes (10 sgRNAs/gene), followed by CRISPR-mediated gene deletion, pharmacologic inhibition, untargeted metabolomics, U-¹³C-glucose and amide-¹⁵N-glutamine isotope tracing, genetic rescue experiments, and patient-derived xenograft (PDX) models. Enasidenib (AG-221) was administered at 5 μM for 24 h in vitro and 50 mg/kg daily in vivo under conditions validated to inhibit wild-type IDH catalytic activity.

Results: Comparative evaluation of clinically developed IDH inhibitors identified AG-221 as the most effective pharmacologic inhibitor of wild-type IDH1/2 catalytic activity under our experimental conditions. A focused CRISPR/Cas9 metabolic screen identified the de novo pyrimidine biosynthetic pathway (CAD, DHODH, and UMPS) as the dominant synthetic-lethal dependency induced by wild-type IDH1/2 inhibition. Uridine supplementation completely rescued this phenotype, confirming pathway specificity. Genetic deletion of IDH1 or IDH2, but not the NAD-dependent mitochondrial isoform IDH3, phenocopied the metabolic rewiring and DHODH inhibitor sensitivity induced by pharmacologic inhibition, genetically establishing wild-type IDH1/2 as the relevant metabolic determinants.

Untargeted metabolomics demonstrated extensive metabolic remodeling following wild-type IDH1/2 inhibition, with the most prominent alterations involving the oxidative pentose phosphate pathway and de novo pyrimidine biosynthesis. U-¹³C-glucose and amide-¹⁵N-glutamine tracing revealed G6PD-dependent activation of the oxPPP, increasing flux into ribose-5-phosphate and phosphoribosyl pyrophosphate while enhancing incorporation of glucose-derived carbon and glutamine-derived nitrogen into pyrimidine intermediates, including orotate and CTP. Genetic deletion or pharmacologic inhibition of G6PD abolished both metabolic rewiring and the acquired dependency on de novo pyrimidine biosynthesis, demonstrating that oxPPP activation is required for this adaptive metabolic state.

Combined inhibition of wild-type IDH1/2 and DHODH produced robust synergistic antileukemic activity (mean ZIP synergy score = 17.11 ± 2.19) across six AML cell lines and six primary AML specimens, including TP53-mutant and venetoclax-relapsed samples. In independent IDH2-mutant and IDH2-wild-type PDX models, dual inhibition significantly reduced leukemia burden, depleted CD34⁺ leukemia stem and progenitor cells, impaired serial transplantation capacity, and significantly prolonged survival (IDH2-mutant: 52 vs. 25 days, P = 0.018; IDH2-wild-type: 50 vs. 22 days, P = 0.0026). Comparable efficacy was observed in TP53-mutant MOLM13 xenografts and MLL-AF9/TP53-knockout murine AML.

Conclusions: Wild-type IDH1/2 function as previously unrecognized regulators of NADPH homeostasis in AML. Their inhibition elicits G6PD-dependent adaptive metabolic rewiring that redirects carbon and nitrogen flux to sustain de novo pyrimidine biosynthesis during redox stress, creating a therapeutically exploitable dependency on DHODH. These findings define a previously unrecognized wild-type IDH1/2–G6PD–DHODH synthetic-lethal axis, uncover a mechanistic link between NADPH homeostasis and nucleotide metabolism, and provide a rationale for targeting this adaptive metabolic circuit in therapy-resistant AML.

Meng Liu, MD: No relevant conflicts of interest to declare.